louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01001806: A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
Official title: A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cataracts
Lead sponsor: Bucci Laser Vision Institute
Sponsor class: OTHER
Collaborators: name: Allergan
First posted: 2009-10-27
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom, or Nevanac. Subjects will be instructed to begin dosing the study medication in the operative eye the day before surgery and continue dosing on the day of surgery. Beginning one hour before surgery, 1 drop of study medication will be instilled by operating room staff approximately every 15 minutes for a total of 3 doses. At the designated time a paracentesis will be performed at the start of the cataract procedure and at least 0.15 cc of aqueous humor will be collected. The sample will be immediately stored on dry ice and shipped to a laboratory for analysis.


Eligibility criteria: Inclusion Criteria:

* Subjects must be 18 years of age or older.
* Scheduled for cataract surgery by phacoemulsification.
* Subject must be willing to comply with all study requirements and be willing to give informed consent.

Exclusion Criteria:

* Any subject that has a history of uveitis or active iritis.
* Subject can have no previous eye surgery, with the exception of refractive surgery, but not within 6 months.
* No ocular use of prostaglandins within 2 weeks of surgery.
* Use of oral, injectable or topical ophthalmic steroids, nonsteroidal anti-inflammatory (NSAIDS) or immunosuppressants within 14 days prior to surgery.
* Contraindications to NSAIDS.
* Active ocular infection.

Primary outcomes:
measure: Peak Aqueous Penetration
timeFrame: day 4 of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Wilkes-Barre
country: United States
facility: Bucci Laser Vision Institute
state: Pennsylvania
Study officials:
affiliation: Bucci Laser Vision Institute
name: Frank A Bucci, Jr.,, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05934006: Comparison of I-FFQ and Two Reference Methods
Official title: Comparison of a Digital Iodine-specific Food Frequency Questionnaire With 24-hour Recall and Urinary Iodine Concentration
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Iodine Deficiency
Keywords: validation
food frequency questionnaire
Lead sponsor: University of Bergen
Sponsor class: OTHER
Collaborators: name: National Dairy Council
name: Institute of Marine Research
First posted: 2023-07-06
Enrollment: 72
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy women aged 18-40 years

Brief summary: Mild-to-moderate iodine deficiency remains a problem in many parts of the world, including Norway. Of particular concern are fertile, pregnant, and lactating women. The Norwegian Dairy Council developed a digital iodine-specific food frequency questionnaire (I-FFQ) for the assessment of iodine intake levels, but it has yet to be validated. The main objective was thus to investigate the relative validity of the I-FFQ by comparing estimates of iodine intake obtained from the I-FFQ against a single 24-hour recall (24HR) and urinary iodine concentration (UIC) in fertile women.


Eligibility criteria: Inclusion Criteria:

* healthy women aged 18-40 years
* sufficient language skills to be able to complete the questionnaires in Norwegian
* be able to meet physically at the study center in Bergen

Exclusion Criteria:

* being pregnant, lactating, or having known thyroid disease

Primary outcomes:
measure: Comparison of FFQ with 24-hour recall
timeFrame: One week
measure: Comparison of FFQ with urinary iodine concentration
timeFrame: One week
Secondary outcomes:
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: University of Bergen
Study officials:
affiliation: University of Bergen
name: Hanne Rosendahl-Riise, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00178906: Acoustical Properties of Speech as Indicators of Suicidal Risk
Official title: Acoustical Properties of Speech as Indicators of Suicidal Risk
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Depression
Keywords: depression
suicide
voice
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 124
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Acutely suicidal depressed patients; non-suicidal depressed patients;

Brief summary: This project is focused on acoustical, sound, analysis of speech in order to identify vocal characteristics of speech that are associated with suicidality. Speech samples will be collected from four populations with different mental health status: suicidal, ideational suicidal, depressed and those in remission from depression, (the control group). Speech of subjects will be recorded during routine diagnostic interview sessions. The speech samples will be acoustically analyzed via digital computer algorithms. The acoustical differences among those groups will be determined based on the statistical analysis.


Eligibility criteria: Inclusion Criteria:

* Age Range: 25 to 65 years of age
* Participants must be depressed or be in remission from depression (have a history of depression)

Exclusion Criteria:

* speech impediment
* intoxication at time of interview

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: Richard Shiavi, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Vanderbilt University
name: Ronald M Salomon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05034406: The Effect of Subcutaneous and Intraperitoneal Anesthesia on Post Laparoscopic Pain
Official title: The Effect of Subcutaneous and Intraperitoneal Instillation of Local Anesthetics on Postoperative Pain After Laparoscopic Varicocelectomy: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Varicocele
Postoperative Pain
Lead sponsor: KBC Split
Sponsor class: OTHER
First posted: 2021-09-05
Enrollment: 60
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Aim of this study is to examine the effects of subcutaneously applied local anesthetics at trocar site in combination with intraoperative intraperitoneal analgesia on duration and character of pain in pediatric patients undergoing laparoscopic varicocelectomy.


Eligibility criteria: Inclusion Criteria:

* pediatric patients with varicocele who underwent laparoscopic varicocelectomy
* pediatric patients whose parents or guardians gave informed consent

Exclusion Criteria:

* patients who received open or microsurgical varicocelectomy
* pediatric patients who underwent conversion to open procedure
* pediatric patients with chronic, metabolic and endocrine diseases
* pediatric patients with systemic infections

Primary outcomes:
measure: Pain (as measured by Visual analogue scale)
timeFrame: 6 hours after surgery
Secondary outcomes:
measure: Pain (as measured by Visual analogue scale)
timeFrame: 2 hours after surgery
measure: Pain (as measured by Visual analogue scale)
timeFrame: 12 hours after surgery
measure: Pain (as measured by Visual analogue scale)
timeFrame: 24 hours after surgery
Other outcomes:
Locations:
city: Split
country: Croatia
facility: University Hospital Split
state: Splitsko-dalmatinska
Study officials:
affiliation: University of Split, School of Medicine
name: Zenon Pogorelić, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00883506: To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and Fed
Official title: Randomized, 3-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions Under Fasting and Fed Conditions.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypertension
Lead sponsor: Sandoz
Sponsor class: INDUSTRY
First posted: 2009-04-17
Enrollment: 24
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet under Fasting and Fed.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.

Primary outcomes:
measure: Bioequivalence based on AUC and Cmax
timeFrame: 50 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Anapharm
name: Eric Masson, Pharm.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03892499: A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers
Official title: An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of Olinciguat (IW-1701)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Cyclerion Therapeutics
Sponsor class: INDUSTRY
First posted: 2019-03-27
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: To evaluate the effect of itraconazole (a potent cytochrome P450 isoenzyme \[CYP\]3A inhibitor) on the pharmacokinetics (PK) of olinciguat


Eligibility criteria: Inclusion Criteria:

* Subject is an ambulatory adult and between 18 and 55 years old (inclusive) at the screening visit
* Subject is in good health and has no clinically significant findings on physical examination
* Body mass index is \> 18 and \< 30 kg/m2 at the screening visit
* Women of reproductive potential must have a negative pregnancy test at screening at at the time of check-in and must agree to use protocol-specified contraception throughout the duration of the study and until 90 days after receiving the final study drug dose
* Men must agree to use protocol-specified contraception and also to not donate sperm throughout the study and until 90 days after receiving the final study drug dose
* Other inclusion criteria per protocol

Exclusion Criteria:

* Any active or unstable clinically significant medical condition
* Use of any prescribed or non-prescribed medication (except for hormonal birth control)
* Other exclusion criteria per protocol

Primary outcomes:
measure: Maximum Observed Plasma Concentration (Cmax) of olinciguat
timeFrame: Predose and up to 8 days post first olinciguat dose
measure: Area under the plasma concentration time curve from time zero (predose) extrapolated to infinity (AUCinf)
timeFrame: Predose and up to 8 days post first olinciguat dose
Secondary outcomes:
measure: Number of subjects with ≥1 treatment-emergent adverse event (TEAE) in Period 1 vs Period 2
timeFrame: 51 days post first olinciguat dose
measure: Cmax of Itraconazole
timeFrame: First Itraconazole dose up to day 8 of Period 2 (Period 2 duration can be up to 13 days)
measure: Area under the concentration-time curve during a dosing interval (AUCtau) for itraconazole and hydroxy-itraconazole
timeFrame: Period 2 (Period 2 duration can be up to 13 days) predose and up to 24 hour after 2nd olinciguat dose
measure: Cmax of hydroxy-Itraconazole
timeFrame: First Itraconazole dose up to day 8 of Period 2 (Period 2 duration can be up to 13 days)
Other outcomes:
Locations:
city: Austin
country: United States
facility: PPD
state: Texas
Study officials:
affiliation: Cyclerion Therapeutics
name: Bina Tejura, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01848899: Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
Official title: The Assesment of Thrombotic Markers Utilizing Ionic Versus Non-Ionic Contrast During Coronary Angiography and Intervention (AToMIC) Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Disease
Keywords: Coronary angiography
Percutaneous coronary intervention
Contrast media
Platelet activity
Thrombin generation
Fibrinolysis
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
Collaborators: name: Guerbet
First posted: 2013-05-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The aim of this study is to determine how two different types of iodinated contrast media (CM) agents, low-osmolar ionic ioxaglate and iso-osmolar non-ionic iodixanol, affect specific markers of thrombogenesis and platelet function in patients undergoing coronary angiography, and if the use of bivalirudin, a direct thrombin inhibitor used during percutaneous coronary intervention (PCI), affects any contrast-related changes in thrombogenesis and platelet function.


Eligibility criteria: Inclusion Criteria:

* Patients must be more than 18 years of age
* referred for coronary angiography and on dual anti-platelet therapy (aspirin and clopidogrel).

Exclusion Criteria:

* on warfarin
* on low molecular weight heparin within 12 hours of coronary angiography or unfractionated heparin with activated clotting time \>150 at time of procedure -on cilostazol
* on persantine
* on non- steroidal anti-inflammatory medications (ibuprofen/motrin/advil, naproxen/aleve, indomethacin, sulindac, etodolac, diclofenac, celecoxib) within 72 hours of procedure
* on prasugrel (not an exclusion criteria for ST-segment elevation myocardial infarction registry
* undergoing coronary angiography via radial access
* undergoing planned diagnostic coronary angiography only
* unable to tolerate dual anti-platelet therapy
* with known allergy to CM
* received CM within 24 hours of coronary angiography
* on dialysis
* do not consent or are unable to give consent
* are participating in another competing study.

Primary outcomes:
measure: Thrombin Generation Test: Baseline
timeFrame: baseline
measure: Thrombin Generation Test: After Coronary Angiography
timeFrame: 1 hour
Secondary outcomes:
measure: Percent Change in Maximal Platelet Aggregation: Epinephrine
timeFrame: Baseline to 1 hour
measure: Percent Change in Maximal Platelet Aggregation: Arachidonic Acid
timeFrame: 1 hour
measure: Percent Change in Maximal Platelet Aggregation: ADP
timeFrame: 1 hour
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: NYU Langone Health
name: Fred Feit, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: NYU Langone Health
name: Binita Shah, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06649799: Comparative Study on Changes in Anterior Chamber Cytokines, Oxidative Stress, and Pupil Size After LenSx and Z8 Femtosecond Lasers
Official title: Comparative Study on Changes in Anterior Chamber Cytokines, Oxidative Stress, and Pupil Size After LenSx and Z8 Femtosecond Lasers
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Cataract
Keywords: cataract; femtosecond laser; cytokines; oxidative stress; miosis;
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2024-10-21
Enrollment: 80
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Femtosecond laser-assisted cataract surgery is rapidly gaining popularity. Among the 5 femtosecond laser platforms available at present for cataract surgery, the Femto LDV Z8 (Ziemer Ophthalmic Systems AG) is a high-frequency system and delivers energy pulses in nanojoule levels, while Lensx platform (Lensx, Alcon Laboratories, Inc.) used a high-energy laser system. In femtosecond laser-assisted cataract surgery, the laser pretreatment is associated with breakdown of blood-aqueous barrier (BAB) associated with increased aqueous total prostaglandin, cytokines and Oxygen-free radicals concentration. The prostaglandin rise immediately after laser pretreatment is further thought to be the causative factor for the intraoperative miosis in femtosecond laser-assisted cataract surgery. However, the analysis of anterior chamber inflammatory factors, oxidative stress, and pupil size after femtosecond laser-assisted cataract surgery between different laser platforms has not been investigated in clinical studies. Understanding the cytokine and chemokine changes related to the laser pretreatment provides better insight into the inflammatory response in femtosecond laser-assisted cataract surgery.


Eligibility criteria: Inclusion Criteria:

Age related cataracts over 50 years old, nuclear grades II-III

Exclusion Criteria:

* Eye diseases: glaucoma, uveitis

  * Systemic diseases: autoimmune diseases such as diabetes and rheumatism ③ Intraoperative complications: ④ Medication history: Over 1 month before surgery, systemic or local hormones, NASIDs ⑤ History of eye surgery (including YAG laser and fundus laser), trauma

Primary outcomes:
measure: PGE2
timeFrame: through study completion, an average of half a year
measure: cytokines (IL-1β、IL-6, IL-8、TNF-a)
timeFrame: through study completion, an average of half a year
measure: MDA
timeFrame: through study completion, an average of half a year
Secondary outcomes:
measure: central corneal thickness
timeFrame: through study completion, an average of half a year
measure: central macular thickness
timeFrame: through study completion, an average of half a year
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: ye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University
state: Zhejiang
Study officials:
References:
Clinical trial NCT06144099: Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Non-cardiac Surgery
Official title: Prothrombin Complex Concentrate and Fresh Frozen Plasma in Viscoelastic Test-based Goal-directed Bleeding Management in Non-Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Prostate Cancer
Spine, Open
Hip Osteoarthritis
Knee Disease
Lead sponsor: Konkuk University Medical Center
Sponsor class: OTHER
First posted: 2023-11-22
Enrollment: 154
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary endpoint of this study is the completion time of hemostasis treatment when administered Fresh frozen plasma (FFP) and frozen powder coagulation factor concentrate (PCC) in goal-directed bleeding management for non-cardiac surgery.


Eligibility criteria: Inclusion Criteria:

* patients undergoing spine surgery
* patients undergoing open radical prostatectomy
* patients undergoing hip arthroplasty
* patients undergoing knee arthroplasty

Exclusion Criteria:

* Patients taking oral anticoagulants,
* Patient taking recombinant factor VII a
* pregnancy

Primary outcomes:
measure: duration from the time diagnosing r-time prolongation to the time achieving bleeding control
timeFrame: 1 min
Secondary outcomes:
measure: Red Blood Cell amount
timeFrame: 1 hour
measure: FFP amount
timeFrame: 1 hour
measure: Platelet amount
timeFrame: 1 hour
measure: r-time
timeFrame: 10 min
measure: CRT-MA
timeFrame: 10 min
measure: CFF-MA
timeFrame: 10 min
measure: Bleeding
timeFrame: 6 hour
measure: oxygenation profile
timeFrame: 1 hour
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05906199: A Study to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract and Aspirin in Diabetic Peripheral Angiopathy.
Official title: A Prospective, Randomized, Active-controlled, Parallel, Open, Multi-center, Phase IV, Exploratory Clinical Trial to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract (Renexin CR) and Aspirin (Aspirin Protect Tab.) in Diabetic Peripheral Angiopathy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetic Peripheral Angiopathy
Lead sponsor: SK Chemicals Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-06-15
Enrollment: 105
Sex: ALL
Minimum age (years): 20
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to compare and evaluate the effect of improving the carotid IMT and lipid level of the Cilostazol/Ginkgo leaf extract group with the aspirin administrated group in patients with diabetic peripheral angiopathy.

Detailed description: A Prospective, Randomized, Active-controlled, Parallel, Open, Multi-center, Phase IV

Eligibility criteria: \<Inclusion Criteria\>

1. Male or female aged between 20 years and 75 years(inclusive)
2. Patients who diagnosed as type 2 diabetes and diabetic peripheral angiopathy
3. Patients with a maximum intra-carotid membrane thickness (maximum IMT) of 0.9 mm or more among the thickest areas, including plaques, in the CCA, ICA, and Bulb three areas of the carotid artery

\<Exclusion Criteria\>

1. Patients who diagnosed with type 1 diabetes, secondary diabetes, or gestational diabetes
2. Patients with cerebrovascular or cardiovascular complications within 6 months of screening (cerebral infarction, transient ischemic seizures, myocardial infarction, unstable angina, coronary artery bypass graft(CABG), PCI, etc.)
3. Patients with bleeding (hemophilia, capillary weakness, intracranial hemorrhage, upper digestive tract hemorrhage, urinary tract hemorrhage, hematopoietic hemorrhage, active digestive ulcers, etc.) or peptic ulcers within 3 months of screening
4. Patient who took anticoagulants, antiplatelet drugs including aspirin, cilostazol, thrombolytic agents, prostaglandin E1 and glucagon-like peptide -1 (GLP-1) receptor agonist within 2 weeks of the baseline

Primary outcomes:
measure: Changes in carotid IMT
timeFrame: 24weeks, 48weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: SKChemicals
state: Gyunggi-do
city: Seoul
country: Korea, Republic of
facility: SK chemicals
Study officials:
References: